Q1 · MEDICINE
Article
Author: Desai, Bipin N. ; Russell, Mark A. ; Askonas, Leslie J. ; Ghoreishi-Haack, Nayereh S. ; Harding, Elizabeth I. ; Chandrakumar, Nizal S. ; Djuric, Stevan W. ; Chen, Helen Y. ; Gierse, James K. ; Yu, Stella S. ; Chen, Barbara B. ; Gasiecki, Alan F. ; Smith, Walter G. ; Parnas, Barry L. ; Highkin, Maureen K. ; Kilpatrick, Brian F. ; Miyashiro, Julie M. ; Haack, Richard A. ; Pyla, E. Yvonne ; Durley, Richard C. ; Kim, Suzanne H. ; Docter, Stephen H. ; Kachur, James F. ; Villani-Price, Doreen ; Corley, David G. ; Krivi, Gwen G. ; Penning, Thomas D.
Leukotriene B(4) (LTB(4)) is a pro-inflammatory mediator that has been implicated in the pathogenesis of a number of diseases including inflammatory bowel disease (IBD) and psoriasis. Since the action of LTA(4) hydrolase is the rate-limiting step for LTB(4) production, this enzyme represents an attractive pharmacological target for the suppression of LTB(4) production. From an in-house screening program, SC-22716 (1, 1-[2-(4-phenylphenoxy)ethyl]pyrrolidine) was identified as a potent inhibitor of LTA(4) hydrolase. Structure-activity relationship (SAR) studies around this structural class resulted in the identification of a number of novel, potent inhibitors of LTA(4) hydrolase, several of which demonstrated good oral activity in a mouse ex vivo whole blood assay.